DeepMed Research

Galderma Group AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: -

Employees: -

Market Cap: $22.9B

Website: http://www.galderma.com/

Clinical Trials

Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Adapalene lotion 0.1%
Drug: Adapalene Lotion Vehicle

First Posted Date: 2008-01-23

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 1067

Registration Number: NCT00599521

Locations: 🇺🇸
East Coast Clinical Research, Inc., Haverhill, Massachusetts, United States
🇺🇸
Dermatology Associates of Rochester, Rochester, New York, United States
🇺🇸
J&S Studies, Inc., Bryan, Texas, United States

and more 30 locations

Treatment of Patients With Blepharitis and Facial Rosacea

Phase 2

Completed

Conditions: Meibomianitis
Blepharitis
Dry Eye

Interventions: Drug: COL-101 (doxycycline, USP) capsules
Drug: placebo

First Posted Date: 2007-11-20

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 70

Registration Number: NCT00560703

Locations: 🇺🇸
Tanner Clinic, Layton, Utah, United States
🇺🇸
Anita Nevyas-Wallace, MD, Bala-Cynwyd, Pennsylvania, United States
🇺🇸
Kentucky Lions Eye Center, Louisville, Kentucky, United States

and more 5 locations

Compassionate Use of Metvix® (Methyl Aminolevulinate) Photodynamic Therapy (PDT) in Subjects With Field Actinic Keratoses, Large/Multiple Superficial Basal Cell Carcinomas (BCCs), or Bowen's Disease

Conditions: Field Actinic Keratoses
Basal Cell Carcinoma
Bowen's Disease

First Posted Date: 2007-09-26

Last Posted Date: 2021-02-18

Lead Sponsor: Galderma R&D

Registration Number: NCT00535080

Comparison of Two Tri-Luma® Maintenance Regimens in the Treatment of Melasma

Phase 4

Completed

Conditions: Melasma

Interventions: Behavioral: Tri-Luma Maintenance regimen

First Posted Date: 2007-07-12

Last Posted Date: 2021-02-17

Lead Sponsor: Galderma R&D

Target Recruit Count: 340

Registration Number: NCT00500162

Locations: 🇧🇷
UNIFESP - Universidade Federal de São Paulo, Sao Paulo, Brazil
🇲🇽
Hospital General de México - Servicio de Dermatología, Mexico City, Mexico

Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma

Phase 3

Completed

Conditions: Basal Cell Carcinoma

Interventions: Drug: Metvix® cream

First Posted Date: 2007-05-15

Last Posted Date: 2023-01-05

Lead Sponsor: Galderma R&D

Target Recruit Count: 102

Registration Number: NCT00473343

Locations: 🇦🇺
Department of Dermatology, St. George Hospital, Kogarah, New South Wales, Australia
🇦🇺
Dermatology Department, The Queen Elisabeth Hospital, Adelaide, South Australia, Australia
🇦🇺
Department of Dermatology, Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 4 locations

Efficacy and Safety of Therapy With Tri-Luma® Cream in Sequence With Glycolic Acid Peels for Melasma

Phase 4

Completed

Conditions: Melasma

Interventions: Drug: Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels

First Posted Date: 2007-05-14

Last Posted Date: 2022-07-29

Lead Sponsor: Galderma R&D

Target Recruit Count: 20

Registration Number: NCT00472966

Locations: 🇺🇸
Skin Care Research, Inc., Boca Raton, Florida, United States

Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma

Phase 3

Completed

Conditions: Basal Cell Carcinoma

Interventions: Radiation: Photodynamic Therapy (PDT)
Drug: Placebo Cream
Drug: Metvix cream

First Posted Date: 2007-05-11

Last Posted Date: 2024-08-05

Lead Sponsor: Galderma R&D

Target Recruit Count: 65

Registration Number: NCT00472108

Locations: 🇺🇸
Texas Dermatology Research Institute, Dallas, Texas, United States
🇺🇸
Department of Dermatology, Roswell Park Cancer Institue, Buffalo, New York, United States
🇺🇸
Department of Dermatology, University of Minnesota Hospital and Clinic, Minneapolis, Minnesota, United States

and more 6 locations

PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Call Carcinoma

Phase 3

Completed

Conditions: Basal Cell Carcinoma

Interventions: Drug: Placebo
Drug: PDT with Metvix 160 mg/g cream

First Posted Date: 2007-05-11

Last Posted Date: 2024-08-06

Lead Sponsor: Galderma R&D

Target Recruit Count: 66

Registration Number: NCT00472043

Locations: 🇦🇺
Department of Dermatology, St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
🇦🇺
Fremantle Dermatology, Fremantle, Western Australia, Australia
🇦🇺
Dept. of Dermatology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

and more 4 locations

Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer

Phase 3

Completed

Conditions: Actinic Keratosis
Basal Cell Carcinoma
Warts
Bowens Disease
Squamous Cell Carcinoma

First Posted Date: 2007-05-11

Last Posted Date: 2025-04-18

Lead Sponsor: Galderma R&D

Target Recruit Count: 82

Registration Number: NCT00472459

Locations: 🇩🇰
Department of Dermatology, Roskilde Amysygehus, Roskilde, Denmark
🇩🇰
Department of Dermatology, Århus Amysygehus, Århus, Denmark
🇩🇪
Klinik für Dermatologie, Venerologie und Allergologie, Campus Charité Mitte, Berlin, Germany

and more 8 locations

Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma

Phase 3

Completed

Conditions: Superficial Basal Cell Carcinoma

Interventions: Drug: Metvix® cream
Procedure: Hand held liquid nitrogen spray cryotherapy

First Posted Date: 2007-05-04

Last Posted Date: 2024-08-19

Lead Sponsor: Galderma R&D

Target Recruit Count: 120

Registration Number: NCT00469417

Locations: 🇮🇹
Spedali di Brescia, Brescia, Italy
🇫🇷
Hôpital Sainte-Marguerite, Marseille, France
🇫🇷
Service de Dermatologie, C.H.U Saint Louis, Paris, France

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy